Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

Company Leadership Update - Robert Hershberg, MD, PhD, has been appointed as the new Chair of the Board of Recursion, effective at the end of the current term, replacing Martin Chavez who is stepping down after more than four years of leadership [1] - Dr Hershberg brings extensive experience in drug discovery and commercialization, having served on Recursion's Board since May 2020 and holding leadership roles at HilleVax, Celgene, and VentiRx Pharmaceuticals [2] - Chris Gibson, CEO and Co-founder of Recursion, expressed excitement about Dr Hershberg's appointment and gratitude for Martin Chavez's contributions to the company's growth [3] Company Overview - Recursion is a clinical-stage TechBio company that decodes biology to industrialize drug discovery, leveraging its proprietary Recursion OS platform and one of the world's largest biological and chemical datasets [4] - The company conducts millions of wet lab experiments weekly and operates one of the most powerful supercomputers in the world, combining technology, biology, and chemistry to advance medicine [4] - Recursion is headquartered in Salt Lake City and has offices in Toronto, Montréal, and the San Francisco Bay Area [5] Industry Impact - Recursion is positioned as a leader in the TechBio space, which is expected to revolutionize the biopharma industry through the intersection of scientific rigor and technology [3] - The company's approach to drug discovery, unconstrained by human bias and enabled by machine learning, represents the future of the industry [2]